The Company leverages its well-established cutting-edge platforms, including monoclonal antibody technology and mRNA technology, to conduct R&D of a number of promising veterinary biological products for pets, such as canine interferon, rabies mRNA vaccine, and canine monoclonal antibodies.
At present, the long-acting canine q-interferon is about to enter the clinical application stage, while both the rabies mRNA vaccine and canine therapeutic monoclonal antibodies have initially achieved promising laboratory results.